Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | F2R | P25116 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL432667 | 1.00 | CYP1A2 (0.36) | CYP1A2ACACBMTNR1AMTNR1BF2R | |
| SCHEMBL30152443 | 0.82 | CTSA (0.39) | ALDH1A1MAPT | |
| SCHEMBL28502599 | 0.82 | CTSA (0.39) | ALDH1A1MAPT | |
| SCHEMBL28502600 | 0.82 | CTSA (0.39) | ALDH1A1MAPT | |
| SCHEMBL4629345 | 0.77 | POLB (0.43) | CYP1A2ALDH1A1POLBHTT | |
| SCHEMBL31401094 | 0.76 | CYP1A2 (0.44) | CYP1A2ACACBALDH1A1MAPTHPGD | |
| SCHEMBL18581761 | 0.74 | ACACB (0.32) | ACACB | |
| SCHEMBL18555597 | 0.74 | ACACB (0.32) | ACACB | |
| SCHEMBL16444969 | 0.74 | CES2 (0.32) | PKM | |
| SCHEMBL430901 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2678338-B1 | PYRAZOLO[1,5-A]PYRIDINES AS TRK INHIBITORS | NOVARTIS AG (CH) | 2015-09-09 | — | — | EP | disclosed |
| US-9102671-B2 | Compounds and compositions as TRK inhibitors | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| EP-2678338-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2014-01-01 | — | — | EP | disclosed |
| US-20130331397-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2013-12-12 | — | — | US | disclosed |
| WO-2012116217-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-08-30 | — | — | WO | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331397-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | CNKSR1, BMP2K, RAF1 | CYP1A2 4325/4885ACACB 1191/4885MTNR1A 1914/4885 |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | TNK2, CNKSR1, BMP2K | CYP1A2 4577/4885ACACB 717/4885MTNR1A 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.